The decision to discontinue further clinical development of Acasunlimab does not impact Genmab’s full‑year 2025 financial ...

With the merger's completion on January 6, 2026, CureVac's era on the public markets will end. The focus will shift entirely to integrating its clinical candidates, particularly in cancer ...

Messenger RNA technology leaders Moderna and BioNTech have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as ...

Now that two mRNA COVID-19 vaccines have been embraced as tools to end the pandemic, their developers are looking for ways to apply the technology to other diseases. They include Pfizer’s COVID ...

LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE)-- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) ...

BioNTech, a biotech company best known for its successful development of a messenger RNA Covid-19 vaccine, is acquiring fellow mRNA company CureVac in a $1.25 billion stock deal that brings together ...

People aiming to get its Comirnaty Covid vaccine won't need a doctor's prescription to do so. This was among several measures being considered by an advisory panel to the CDC. Investors were cheered ...

A logo of BioNTech is pictured at the headquarter of biopharmaceutical company BioNTech, one of the laboratories in the race to develop a coronavirus vaccine, in Mainz, western Germany. (Photo by Yann ...

BioNTech has added evidence that PD-(L)1xVEGF-A bispecifics can unseat Keytruda. The German biotech reported an 18-month overall survival rate of 69.7% in a phase 1b/2 breast cancer trial, handily ...

BioNTech CEO Ugur Sahin is taking a big pay cut in 2021, but his large stake in the German company he co-founded still qualifies him for billionaire status. Sahin received a pay package worth 11.59 ...

The JN.1 Novavax vaccine is an alternative to the LP.8.1 Pfizer-BioNTech and Moderna vaccines that were rolled out in October ...